Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2011

01-04-2011 | Article

Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes

Authors: M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, D. M. Pollock

Published in: Diabetologia | Issue 4/2011

Login to get access

Abstract

Aims/hypothesis

Activation of endothelin receptor-A (ETA) increases glomerular permeability to albumin (Palb) and elevates pro-inflammatory markers in hyperglycaemic rats.

Methods

Male Sprague–Dawley rats were given streptozotocin (n = 32) or saline (sham; n = 32). Half of the animals in each group received the ETA-selective antagonist, ABT-627 (atrasentan; orally), beginning immediately after hyperglycaemia was confirmed. Glomeruli were isolated by sieving techniques and Palb determined from the change in glomerular volume induced by oncotic gradients of albumin. Glomerular nephrin levels were assessed by immunofluorescence, whereas urinary nephrin was measured by immunoassay.

Results

At 3 and 6 weeks after streptozotocin injection, proteinuria was significantly increased compared with sham controls and significantly reduced by ABT-627 treatment. Palb was also increased at 3 and 6 weeks post-streptozotocin. ABT-627 had no effect on Palb or protein excretion in sham control rats. In glomeruli isolated from hyperglycaemic rats, incubation with BQ-123, a selective ETA antagonist, reduced Palb, whereas BQ-788, a selective endothelin receptor-B antagonist had no effect (n = 6 rats per group, 5–8 glomeruli per rat). Glomerular and plasma content of soluble intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 were significantly increased 6 weeks after streptozotocin (ELISA). ABT-627 attenuated these increases. After 6 weeks of hyperglycaemia, glomerular nephrin content was decreased with a concurrent increase in urinary nephrin excretion. ABT-627 prevented glomerular nephrin loss in hyperglycaemic rats (n = 5–8 rats per group; eight groups).

Conclusions/interpretation

These observations support the hypothesis that endothelin-1, via the ETA receptor, directly increases Palb, possibly via nephrin loss, as well as early inflammation in the hyperglycaemic rat.
Literature
1.
Held PJ, Brunner F, Odaka M, Garcia JR, Port FK, Gaylin DS (1990) Five-year survival for end-stage renal disease patients in the United States, Europe, and Japan, 1982 to 1987. Am J Kidney Dis 15:451–457PubMed
2.
Breyer JA, Bain RP, Evans JK et al (1996) Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 50:1651–1658PubMedCrossRef
3.
Badr KF, Munger KA, Sugiura M, Snajdar RM, Schwartzberg M, Inagami T (1989) High and low affinity binding sites for endothelin on cultured rat glomerular mesangial cells. Biochem Biophys Res Commun 161:776–781PubMedCrossRef
4.
Rebibou JM, He CJ, Delarue F et al (1992) Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 7:288–292PubMed
5.
Tomita K, Nonoguchi H, Marumo F (1992) Regulation of NaCl transport by endothelin in renal tubules. Semin Nephrol 12:30–36PubMed
6.
Firth JD, Ratcliffe PJ, Raine AE, Ledingham JG (1988) Endothelin: an important factor in acute renal failure? Lancet 2:1179–1182PubMedCrossRef
7.
Ruiz-Ortega M, Gomez-Garre D, Alcazar R et al (1994) Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens Suppl 12:S51–S58PubMed
8.
Hocher B, Lun A, Priem F, Neumayer HH, Raschack M (1998) Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol 31(Suppl 1):S492–S495PubMedCrossRef
9.
Fukui M, Nakamura T, Ebihara I et al (1993) Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 122:149–156PubMed
10.
Khan MA, Dashwood MR, Mumtaz FH, Thompson CS, Mikhailidis DP, Morgan RJ (1999) Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 83:261–267PubMedCrossRef
11.
Shin SJ, Hsiao PJ, Hsieh MC, Lee YJ, Tsai JH (1999) Increased urinary endothelin-1 excretion in newly diagnosed type 2 diabetic patients. Kaohsiung J Med Sci 15:589–596PubMed
12.
Sasser JM, Sullivan JC, Hobbs JL et al (2007) Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18:143–154PubMedCrossRef
13.
Gagliardini E, Corna D, Zoja C et al (2009) Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 297:F1448–F1456PubMedCrossRef
14.
Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73–80PubMedCrossRef
15.
Sugimoto H, Shikata K, Hirata K et al (1997) Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 46:2075–2081PubMedCrossRef
16.
Viberti GC, Messent J (1991) Risk factors for renal and cardiovascular disease in diabetic patients. Cardiology 79(Suppl 1):55–61PubMedCrossRef
17.
Langham RG, Kelly DJ, Cox AJ et al (2002) Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45:1572–1576PubMedCrossRef
18.
Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA (2004) Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 43:636–650PubMedCrossRef
19.
Opgenorth TJ, Adler AL, Calzadilla SV et al (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473–481PubMed
20.
Misra RP (1972) Isolation of glomeruli from mammalian kidneys by graded sieving. Am J Clin Pathol 58:135–139PubMed
21.
Savin VJ, Sharma R, Lovell HB, Welling DJ (1992) Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3:1260–1269PubMed
22.
Wenzel RR, Littke T, Kuranoff S et al (2009) Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20:655–664PubMedCrossRef
23.
Opocensky M, Kramer HJ, Backer A et al (2006) Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48:965–971PubMedCrossRef
24.
Hocher B, Schwarz A, Reinbacher D et al (2001) Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87:161–169PubMedCrossRef
25.
Morigi M, Buelli S, Zanchi C et al (2006) Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 169:1965–1975PubMedCrossRef
26.
Harita Y, Kurihara H, Kosako H et al (2009) Phosphorylation of nephrin triggers Ca2+ signaling by recruitment and activation of phospholipase C-γ1. J Biol Chem 284:8951–8962PubMedCrossRef
27.
Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM (2010) Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 56:942–949PubMedCrossRef
28.
Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z (2001) Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44:874–877PubMedCrossRef
29.
Collino F, Bussolati B, Gerbaudo E et al (2008) Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 294:F1185–F1194PubMedCrossRef
30.
Shikata K, Makino H (2001) Role of macrophages in the pathogenesis of diabetic nephropathy. Contrib Nephrol 134:46–54PubMedCrossRef
31.
Luft FC, Mervaala E, Muller DN et al (1999) Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 33:212–218PubMed
32.
Rothlein R, Wegner C (1992) Role of intercellular adhesion molecule-1 in the inflammatory response. Kidney Int 41:617–619PubMedCrossRef
33.
Galkina E, Ley K (2006) Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 17:368–377PubMedCrossRef
34.
Hirata K, Shikata K, Matsuda M et al (1998) Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41:185–192PubMedCrossRef
35.
Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH (2005) Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16:1711–1722PubMedCrossRef
36.
Luster AD (1998) Chemokines–chemotactic cytokines that mediate inflammation. N Engl J Med 338:436–445PubMedCrossRef
37.
Wada T, Furuichi K, Sakai N et al (2000) Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58:1492–1499PubMedCrossRef
38.
Rovin BH, Tan LC (1993) LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43:218–225PubMedCrossRef
39.
Ihm CG, Park JK, Hong SP et al (1998) A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 79:33–37PubMedCrossRef
40.
Schena FP, Gesualdo L, Grandaliano G, Montinaro V (1997) Progression of renal damage in human glomerulonephritides: is there sleight of hand in winning the game? Kidney Int 52:1439–1457PubMedCrossRef
41.
Kanamori H, Matsubara T, Mima A et al (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360:772–777PubMedCrossRef
42.
Hayasaki Y, Nakajima M, Kitano Y, Iwasaki T, Shimamura T, Iwaki K (1996) ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Biochem Biophys Res Commun 229:817–824PubMedCrossRef
43.
Chen P, Shibata M, Zidovetzki R, Fisher M, Zlokovic BV, Hofman FM (2001) Endothelin-1 and monocyte chemoattractant protein-1 modulation in ischemia and human brain-derived endothelial cell cultures. J Neuroimmunol 116:62–73PubMedCrossRef
Metadata
Title
Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes
Authors
M. A. Saleh
E. I. Boesen
J. S. Pollock
V. J. Savin
D. M. Pollock
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-2021-4

Other articles of this Issue 4/2011

Diabetologia 4/2011 Go to the issue

Article

Knockdown of the gene encoding Drosophila tribbles homologue 3 (Trib3) improves insulin sensitivity through peroxisome proliferator-activated receptor-γ (PPAR-γ) activation in a rat model of insulin resistance

Article

Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis

Erratum

Erratum to: Association of glucose metabolism with diastolic function along the diabetic continuum

Article

Oltipraz upregulates the nuclear respiratory factor 2 alpha subunit (NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice

Short Communication

Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1)

Short Communication

Effects of a lifestyle intervention in metabolically benign and malign obesity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits